Recently, there has been a lot of excitement about a new treatment for diabetes developed by Vertex Pharmaceuticals. This treatment uses human embryonic stem cells (ESCs) and was reported in the news as a major breakthrough in medical research. Many articles describe it as a significant step towards finding a solution for type 1 diabetes, which is often considered a challenging medical problem.
However, while the media has focused heavily on this treatment, the ethical considerations surrounding it have not received as much attention. The process of obtaining embryonic stem cells involves destroying the embryos from which these cells are taken. This raises important bioethical questions that are often overlooked. According to recent bioethics laws, research involving embryonic stem cells no longer requires special permission; researchers only need to declare their intentions.
Interestingly, while this new treatment from Vertex is gathering lots of attention, it is not the first successful treatment for diabetes using stem cells. Over a year ago, Chinese doctors reported healing a 59-year-old man with type 2 diabetes through a different type of stem cell called induced pluripotent stem cells (iPS). After receiving the treatment, he was able to stop taking insulin for 33 months.
Moreover, in September, another study reported that a 25-year-old woman with type 1 diabetes started producing her own insulin less than three months after receiving a transplant of reprogrammed stem cells. Two other patients received the same treatment with similarly positive results. Additionally, in April, a university hospital in Kyoto successfully transplanted pancreatic cells made from iPS into a patient with type 1 diabetes, with plans to treat another patient soon.
Despite these promising results with iPS cells, they have not received the same level of media coverage as the treatment from Vertex. While it’s important to validate the findings with larger studies, there seems to be a disparity in how these different treatments are reported.
One reason for the difference in coverage might be the challenges in scaling up and commercializing iPS treatments, which can be expensive. Meanwhile, embryonic stem cells can be readily obtained from surplus embryos, making them easier and cheaper to use. This raises crucial questions about whether profit is being prioritized over ethical considerations regarding human dignity.
In summary, while the recent advancements using embryonic stem cells are exciting, it’s essential to also recognize and give attention to other successful treatments that might not involve the same ethical dilemmas. These treatments not only show promise but also could lead to solutions that respect human life and dignity.
This article has been translated and simplified by artificial intelligence from a French article “Thérapie cellulaire contre le diabète : les CSEh sous les projecteurs, les iPS passées sous silence”
It may therefore contain errors. The French version is the reference version..